8-K Announcements
6Material company update
Apr 29, 2026·SEC
Material company update
Mar 23, 2026·SEC
Material company update
Mar 12, 2026·SEC
Crescent Biopharma, Inc.(CBIO)Earnings, Financials & Key Ratios
CBIO•NASDAQ
Price updated Jun 11, 2026
AboutCrescent Biopharma, Inc., an oncology company, develops therapies for cancer patients. Its pipeline includes a PD-1 x VEGF bispecific antibody, as well as novel antibody-drug conjugates to treat solid tumors. The company is headquartered in Waltham, Massachusetts.Show more
- Revenue$11M
- EBITDA-$153M-205.9%
- Net Income-$154M-217.3%
- EPS (Diluted)-12.81-815.0%
- Gross Margin100%
- EBITDA Margin-1406.75%
- Operating Margin-1407.52%
- Net Margin-1419.61%
- ROE-164.18%+61.2%
- Debt/Equity0.01
- Interest Coverage-68.54-32.1%
CBIO Key Insights
Crescent Biopharma, Inc. (CBIO) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Company is almost debt free
- ✓Strong Piotroski F-Score: 7/9
- ✓Momentum leader: RS Rating 83 (top 17%)
- ✓Share count reduced 46.6% through buybacks
- ✓Trading at only 0.9x book value
✗Weaknesses
- ✗Profits declining 24.7% over 5 years
- ✗Negative free cash flow
- ✗Low quality earnings: Net income not backed by cash flow
- ✗Trading more than 30% below 52-week high
- ✗Low asset turnover indicates capital-intensive operations
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when CBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CBIO Price & Volume
Crescent Biopharma, Inc. (CBIO) stock price & volume — 10-year historical chart
Loading chart...
CBIO Growth Metrics
Crescent Biopharma, Inc. (CBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-5.97%
5 Years1.31%
3 Years424.86%
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM-206.18%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM-442.79%
Return on Capital
10 Years-74.67%
5 Years-103.8%
3 Years-127.95%
Last Year-132.59%
CBIO Recent Earnings
Crescent Biopharma, Inc. (CBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 6/12 qtrs (50%)●Beat Revenue 2/12 qtrs (100%)
Q2 2026Latest
Apr 29, 2026EPS
$0.70
Est $0.85
+17.6%
Revenue
$1M
Est $357,143
+180.0%
Q1 2026
Feb 26, 2026EPS
$4.01
Est $2.22
-80.6%
Revenue
$11M
Est $10M
+8.4%
Q4 2025
Nov 6, 2025EPS
$1.27
Est $1.01
-25.7%
Revenue
—
Q3 2025
Jul 31, 2025EPS
$4.93
Est $2.69
-83.3%
Revenue
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 29, 2026 | $0.70vs $0.85+17.6% | $1Mvs $357,143+180.0% |
| Q1 2026 | Feb 26, 2026 | $4.01vs $2.22-80.6% | $11Mvs $10M+8.4% |
| Q4 2025 | Nov 6, 2025 | $1.27vs $1.01-25.7% | — |
| Q3 2025 | Jul 31, 2025 | $4.93vs $2.69-83.3% | — |
Based on last 12 quarters of dataView full earnings history →
CBIO Peer Comparison
Crescent Biopharma, Inc. (CBIO) competitors in Oncology Therapeutics Developers — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 RCUS | 2.35B | 23.30 | -7.08 | -4.26% | -156.36% | -68.97% | 0.16 | |
 IMVT | 6.75B | 32.88 | -11.87 | -68.16% | 0.00 | |||
 KYMR | 6.77B | 82.96 | -22.48 | -16.72% | -6.12% | -25.02% | 0.05 | |
 TPST | 5.55M | 1.25 | -0.20 | -7.3% | 1.22 | |||
 AGEN | 141.17M | 3.39 | -997.06 | 10.37% | 52.16% | |||
 NKTR | 1.16B | 59.21 | -6.09 | -43.89% | -284.18% | -87% | 1.66 | |
 CRVS | 975.45M | 11.60 | -21.89 | -38.92% | 0.02 | |||
 EXEL | 13.59B | 53.50 | 19.24 | 6.98% | 35.08% | 40.21% | 0.08 |
Compare CBIO vs Peers
Crescent Biopharma, Inc. (CBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
CBIO Income Statement
Crescent Biopharma, Inc. (CBIO) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 0 | 0 | 0 | 10.16M | 1.16M | 75K | 10K | 0 | 10.84M | 11.88M |
Revenue Growth % | -100% | - | - | - | -88.59% | -93.53% | -86.67% | -100% | - | - |
Cost of Goods Sold | 263.54K | 275.12K | 899.3K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
COGS % of Revenue | - | - | - | - | - | - | - | - | - | - |
Gross Profit | -263.54K▲ 0% | -275.12K▼ 4.4% | -899.3K▼ 226.9% | 0▲ 100.0% | 1.16M▲ 0% | 75K▼ 93.5% | 10K▼ 86.7% | 0▼ 100.0% | 10.84M▲ 0% | 11.88M▲ 0% |
Gross Margin % | - | - | - | - | 100% | 100% | 100% | - | 100% | 100% |
Gross Profit Growth % | - | -4.39% | -226.87% | 100% | - | -93.53% | -86.67% | -100% | - | - |
Operating Expenses | 33.67M | 51.51M | 61.39M | 61.67M | 64.61M | 47.48M | 39.29M | 49.9M | 163.48M | 175.02M |
OpEx % of Revenue | - | - | - | 606.84% | 5570.69% | 63304.43% | 392852.93% | - | 1507.52% | - |
Selling, General & Admin | 9.83M | 11.41M | 14.36M | 16.74M | 17.12M | 19.09M | 19.21M | 16.32M | 25.39M | 29.66M |
SG&A % of Revenue | - | - | - | 164.75% | 1475.76% | 25449.33% | 192130% | - | 234.14% | - |
Research & Development | 24.1M | 40.09M | 47.03M | 44.93M | 47.49M | 28.39M | 20.07M | 28.06M | 138.09M | 145.36M |
R&D % of Revenue | - | - | - | 442.09% | 4094.92% | 37854.51% | 200716.56% | - | 1273.39% | - |
Other Operating Expenses | -263.54K | 0 | 0 | 0 | 0 | 443 | 637 | 5.51M | 0 | 0 |
Operating Income | -33.93M▲ 0% | -51.51M▼ 51.8% | -61.39M▼ 19.2% | -51.51M▲ 16.1% | -63.45M▼ 23.2% | -47.4M▲ 25.3% | -39.28M▲ 17.1% | -49.9M▼ 27.0% | -152.63M▼ 205.9% | -163.14M▲ 0% |
Operating Margin % | - | - | - | -506.84% | -5470.69% | -63204.43% | -392752.93% | - | -1407.52% | -1372.85% |
Operating Income Growth % | -6.33% | -51.79% | -19.19% | 16.09% | -23.18% | 25.29% | 17.15% | -27.05% | -205.89% | - |
EBITDA | -33.67M | -51.23M | -60.49M | -51.24M | -63.18M | -47.2M | -39.12M | -49.86M | -152.55M | -162.99M |
EBITDA Margin % | - | - | - | -504.17% | -5447.87% | -62928.24% | -391219.92% | - | -1406.75% | -1371.61% |
EBITDA Growth % | -6.13% | -52.16% | -18.07% | 15.29% | -23.31% | 25.3% | 17.11% | -27.45% | -205.94% | -209.73% |
D&A (Non-Cash Add-back) | 263.54K | 275.12K | 899.3K | 270.75K | 264.6K | 207.15K | 153.3K | 35.17K | 84K | 148K |
EBIT | -33.93M | -51.5M | -57.89M | -51.51M | -63.45M | -47.4M | -39.27M | -44.21M | -149.76M | -159M |
Net Interest Income | 651.21K | 3.23M | 3.5M | 482.49K | 19.77K | 714.52K | 2.38M | 149.17K | 690K | 3.06M |
Interest Income | 651.21K | 3.23M | 3.5M | 482.49K | 19.77K | 714.52K | 2.38M | 1M | 2.88M | 4.13M |
Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 852K | 2.19M | 1.07M |
Other Income/Expense | 651.21K | 3.23M | 3.5M | 482.49K | 19.77K | 714.96K | 2.38M | 1.37M | 690K | 3.06M |
Pretax Income | -33.28M▲ 0% | -48.27M▼ 45.0% | -57.89M▼ 19.9% | -51.03M▲ 11.9% | -63.43M▼ 24.3% | -46.69M▲ 26.4% | -36.9M▲ 21.0% | -48.52M▼ 31.5% | -151.94M▼ 213.1% | -160.08M▲ 0% |
Pretax Margin % | - | - | - | -502.09% | -5468.98% | -62251.15% | -368987.83% | - | -1401.16% | -1347.11% |
Income Tax | 0 | 3.23M | -3.78M | 0 | 0 | 0 | 0 | 0 | 2M | 2M |
Effective Tax Rate % | 0% | -6.69% | 6.52% | 0% | 0% | 0% | 0% | 0% | -1.32% | -1.25% |
Net Income | -33.28M▲ 0% | -48.27M▼ 45.0% | -54.12M▼ 12.1% | -51.03M▲ 5.7% | -63.43M▼ 24.3% | -46.69M▲ 26.4% | -36.9M▲ 21.0% | -48.52M▼ 31.5% | -153.94M▼ 217.3% | -162.08M▲ 0% |
Net Margin % | - | - | - | -502.09% | -5468.98% | -62251.74% | -368994.2% | - | -1419.61% | -1363.94% |
Net Income Growth % | -4.63% | -45.05% | -12.1% | 5.71% | -24.3% | 26.39% | 20.97% | -31.5% | -217.25% | -206.18% |
Net Income (Continuing) | -33.28M | -48.27M | -57.89M | -51.03M | -63.43M | -46.69M | -36.9M | -48.52M | -153.94M | -162.08M |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
EPS (Diluted) | -1.13▲ 0% | -1.18▼ 4.4% | -1.34▼ 13.6% | -1.12▲ 16.4% | -1.23▼ 9.8% | -0.89▲ 27.6% | -0.58▲ 34.8% | -1.40▼ 141.4% | -12.81▼ 815.0% | -5.33▲ 0% |
EPS Growth % | 24.67% | -4.42% | -13.56% | 16.42% | -9.82% | 27.64% | 34.83% | -141.38% | -815% | -442.79% |
EPS (Basic) | -1.13 | -1.18 | -1.34 | -1.12 | -1.23 | -0.89 | -0.58 | -1.40 | -12.81 | - |
Diluted Shares Outstanding | 29.4M | 41.04M | 43.25M | 45.72M | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M | 30.4M |
Basic Shares Outstanding | 29.4M | 41.04M | 43.25M | 45.72M | 51.45M | 52.53M | 63.34M | 19.5M | 10.41M | 30.4M |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
CBIO Balance Sheet
Crescent Biopharma, Inc. (CBIO) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 127.22M | 212.27M | 162.53M | 138.27M | 90.79M | 50.71M | 43.79M | 34.8M | 236.66M | 195.56M |
Cash & Short-Term Investments | 123.92M | 209.92M | 158.2M | 137.04M | 90.25M | 47.87M | 41.79M | 34.77M | 213.19M | 189.16M |
Cash Only | 123.92M | 209.92M | 158.2M | 137.04M | 90.25M | 47.87M | 41.79M | 34.77M | 213.19M | 189.16M |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 101.95K | 413.12K | 185.95K | 2.15K | 1.35K | 144.02K | 175.82K | 0 | 18M | 0 |
Days Sales Outstanding | - | - | - | 0.08 | 0.42 | 700.88 | 6.42K | - | 605.87 | 138.22 |
Inventory | 0 | -405 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - |
Other Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 38K | 5.46M | 6.4M |
Total Non-Current Assets | 1.36M | 2.57M | 5.44M | 4.56M | 3.56M | 1.1M | 1.53M | 813K | 3.64M | 3.57M |
Property, Plant & Equipment | 1.11M | 957.23K | 3.83M | 2.95M | 1.95M | 751.17K | 767.83K | 0 | 2.31M | 2.3M |
Fixed Asset Turnover | - | - | - | 3.45x | 0.60x | 0.10x | 0.01x | - | 4.68x | 5.42x |
Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 213K |
Other Non-Current Assets | 256.68K | 1.61M | 1.61M | 1.61M | 1.61M | 344.71K | 757.91K | 813K | 1.32M | 1.27M |
Total Assets | 128.58M▲ 0% | 214.84M▲ 67.1% | 167.97M▼ 21.8% | 142.83M▼ 15.0% | 94.35M▼ 33.9% | 51.81M▼ 45.1% | 45.32M▼ 12.5% | 35.62M▼ 21.4% | 240.29M▲ 574.7% | 199.13M▲ 0% |
Asset Turnover | - | - | - | 0.07x | 0.01x | 0.00x | 0.00x | - | 0.05x | 0.06x |
Asset Growth % | 203.35% | 67.08% | -21.82% | -14.97% | -33.95% | -45.08% | -12.53% | -21.4% | 574.66% | 6615.15% |
Total Current Liabilities | 8.17M | 8.76M | 10.95M | 12.43M | 11.82M | 8.88M | 6.84M | 9.61M | 36.07M | 14.19M |
Accounts Payable | 2.65M | 2.66M | 1.44M | 2.09M | 2.11M | 970.19K | 868.12K | 107K | 10M | 1.19M |
Days Payables Outstanding | 3.67K | 3.53K | 582.69 | - | - | - | - | - | - | - |
Short-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 435K | 453K |
Deferred Revenue (Current) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.16M | 7.27M |
Other Current Liabilities | 78.03K | 98.77K | 3.03M | 3.91M | 2.5M | 2.97M | 2.96M | 76K | 21.48M | 9.43M |
Current Ratio | 15.56x | 24.22x | 14.84x | 11.13x | 7.68x | 5.71x | 6.41x | 3.62x | 6.56x | 13.78x |
Quick Ratio | 15.56x | 24.22x | 14.84x | 11.13x | 7.68x | 5.71x | 6.41x | 3.62x | 6.56x | 13.78x |
Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | 138.22 |
Total Non-Current Liabilities | 707K | 611.62K | 2.82M | 2.18M | 918.61K | 0 | 66.84K | 41.48M | 1.21M | 1.09M |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 37.48M | 1.21M | 1.09M |
Capital Lease Obligations | 0 | 0 | 2.82M | 1.92M | 918.61K | 0 | 66.84K | 0 | 0 | 2.76M |
Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 707K | 611.62K | 0 | 264.33K | 0 | 0 | 0 | 4M | 0 | 0 |
Total Liabilities | 8.88M | 9.38M | 13.77M | 14.61M | 12.74M | 8.88M | 6.9M | 51.1M | 37.28M | 15.28M |
Total Debt | 0 | 0 | 3.62M | 2.82M | 1.92M | 918.55K | 808.4K | 37.48M | 1.64M | 1.54M |
Net Debt | -123.92M | -209.92M | -154.58M | -134.22M | -88.33M | -46.95M | -40.98M | 2.72M | -211.55M | -187.62M |
Debt / Equity | - | - | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | - | 0.01x | 0.01x |
Debt / EBITDA | - | - | - | - | - | - | - | - | - | -0.01x |
Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | 1.15x |
Interest Coverage | - | - | - | - | - | - | - | -51.89x | -68.54x | -148.19x |
Total Equity | 119.7M▲ 0% | 205.46M▲ 71.6% | 154.2M▼ 25.0% | 128.22M▼ 16.8% | 81.6M▼ 36.4% | 42.93M▼ 47.4% | 38.41M▼ 10.5% | -15.48M▼ 140.3% | 203.01M▲ 1411.5% | 183.85M▲ 0% |
Equity Growth % | 239.09% | 71.65% | -24.95% | -16.85% | -36.36% | -47.39% | -10.52% | -140.29% | 1411.53% | 10586.95% |
Book Value per Share | 4.07 | 5.01 | 3.56 | 2.80 | 1.59 | 0.82 | 0.61 | -0.79 | 19.49 | 6.05 |
Total Shareholders' Equity | 119.7M | 205.46M | 154.2M | 128.22M | 81.6M | 42.93M | 38.41M | -15.48M | 203.01M | 183.85M |
Common Stock | 34.36K | 43.16K | 43.47K | 49.02K | 52.31K | 54.38K | 64.39K | 1K | 28K | 28K |
Retained Earnings | -152.28M | -200.55M | -258.44M | -309.47M | -372.9M | -419.59M | -456.49M | -17.87M | -171.81M | -195.09M |
Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CBIO Cash Flow Statement
Crescent Biopharma, Inc. (CBIO) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | -29.77M | -43.33M | -51.98M | -39.24M | -57.49M | -46.46M | -34.88M | -31.1M | -71.53M | -75.36M |
Operating CF Margin % | - | - | - | -386.13% | -4956.99% | -61943.32% | -348799.03% | - | -659.65% | - |
Operating CF Growth % | -0.12% | -45.56% | -19.97% | 24.51% | -46.5% | 19.19% | 24.92% | 10.84% | -130.02% | -741.08% |
Net Income | -33.28M | -48.27M | -57.89M | -51.03M | -63.43M | -46.69M | -36.9M | -37.88M | -149.94M | -162.08M |
Depreciation & Amortization | 263.54K | 275.12K | 899.3K | 270.75K | 264.6K | 207.15K | 153.3K | 35.17K | 84K | 715K |
Stock-Based Compensation | 3.76M | 4.59M | 6.22M | 6.9M | 6.09M | 3.86M | 3.56M | 4.77M | 13.3M | 11.42M |
Deferred Taxes | 0 | 0 | 0 | 0 | 2.17K | 0 | 0 | 0 | 0 | -831K |
Other Non-Cash Items | 0 | 168 | 0 | 680.85K | 749.04K | 828.51K | 864.87K | 814.48K | 78.4M | -29.56M |
Working Capital Changes | -511.64K | 80.11K | -1.21M | 3.93M | -1.17M | -4.66M | -2.56M | 1.16M | -13.37M | -10.2M |
Change in Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -18M | 18M |
Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Change in Payables | 1.06M | 16.49K | -1.23M | 654.28K | 17.68K | -1.14M | -102.08K | -538.81K | 2.08M | -6.37K |
Cash from Investing | -294.11K | -125.62K | -144.93K | -68.51K | -14.94K | -84.19K | -21.39K | 20.03K | -72.92M | -81.07M |
Capital Expenditures | -294.11K | -125.62K | -144.93K | -68.51K | -14.94K | -84.19K | -21.39K | -9.97K | -919K | -955K |
CapEx % of Revenue | - | - | - | 0.67% | 1.29% | 112.25% | 213.94% | - | 8.47% | 8.04% |
Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 30K | 0 | 0 |
Investments | - | - | - | - | - | - | - | - | - | - |
Other Investing | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -72M | -82.33M |
Cash from Financing | 113.95M | 129.45M | 412.91K | 18.14M | 10.72M | 4.16M | 28.82M | 5.4K | 322.98M | 316.04M |
Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Equity Issued (Net) | 113.57M | 128.43M | 412.91K | 17.82M | 10.7M | 4.16M | 28.71M | 5.4K | -172K | 177.43M |
Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -177K | -177K |
Other Financing | 373.38K | 1.02M | 0 | 319.3K | 25.03K | 0 | 116.5K | 0 | 323.16M | 138.6M |
Net Change in Cash | 83.88M▲ 0% | 85.99M▲ 2.5% | -51.72M▼ 160.1% | -21.17M▲ 59.1% | -46.78M▼ 121.0% | -42.38M▲ 9.4% | -6.08M▲ 85.7% | -31.07M▼ 411.2% | 178.53M▲ 674.6% | 183.55M▲ 0% |
Free Cash Flow | -30.06M▲ 0% | -43.46M▼ 44.6% | -52.13M▼ 20.0% | -39.31M▲ 24.6% | -57.5M▼ 46.3% | -46.54M▲ 19.1% | -34.9M▲ 25.0% | -31.11M▲ 10.9% | -72.45M▼ 132.9% | -27.36M▲ 0% |
FCF Margin % | - | - | - | -386.8% | -4958.28% | -62055.57% | -349012.97% | - | -668.12% | -230.27% |
FCF Growth % | 1.23% | -44.55% | -19.96% | 24.59% | -46.28% | 19.06% | 25.01% | 10.87% | -132.9% | -1701.31% |
FCF per Share | -1.02 | -1.06 | -1.21 | -0.86 | -1.12 | -0.89 | -0.55 | -1.60 | -6.96 | -0.90 |
FCF Conversion (FCF/Net Income) | 0.89x | 0.90x | 0.96x | 0.77x | 0.91x | 1.00x | 0.95x | 0.64x | 0.46x | 0.17x |
Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
CBIO Key Ratios
Crescent Biopharma, Inc. (CBIO) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -42.94% | -29.69% | -30.09% | -36.14% | -60.46% | -74.98% | -90.72% | -423.13% | -164.18% | -100.86% |
| Return on Invested Capital (ROIC) | - | - | - | - | - | - | - | - | - | 1352.63% |
| Gross Margin | - | - | - | - | 100% | 100% | 100% | - | 100% | 100% |
| Net Margin | - | - | - | -502.09% | -5468.98% | -62251.74% | -368994.2% | - | -1419.61% | -1363.94% |
| Debt / Equity | - | - | 0.02x | 0.02x | 0.02x | 0.02x | 0.02x | - | 0.01x | 0.01x |
| Interest Coverage | - | - | - | - | - | - | - | -51.89x | -68.54x | -148.19x |
| FCF Conversion | 0.89x | 0.90x | 0.96x | 0.77x | 0.91x | 1.00x | 0.95x | 0.64x | 0.46x | 0.17x |
| Revenue Growth | -100% | - | - | - | -88.59% | -93.53% | -86.67% | -100% | - | - |
Related:CBIO Dividend History·CBIO Revenue History·CBIO Price History·CBIO P/E History·CBIO Financial Ratios·CBIO Institutional Holders
CBIO SEC Filings & Documents
Crescent Biopharma, Inc. (CBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
CBIO Frequently Asked Questions
Crescent Biopharma, Inc. (CBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Crescent Biopharma, Inc. (CBIO) reported $11.9M in revenue for fiscal year 2025. This represents a 212% increase from $3.8M in 2011.
Crescent Biopharma, Inc. (CBIO) grew revenue by 0.0% over the past year. Growth has been modest.
Crescent Biopharma, Inc. (CBIO) reported a net loss of $162.1M for fiscal year 2025.
Dividend & Returns
Crescent Biopharma, Inc. (CBIO) has a return on equity (ROE) of -164.2%. Negative ROE indicates the company is unprofitable.
Crescent Biopharma, Inc. (CBIO) had negative free cash flow of $27.4M in fiscal year 2025, likely due to heavy capital investments.